ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.8800
+0.0500 (+2.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.8300
Open1.8400
Bid1.8800 x 1400
Ask2.1000 x 900
Day's Range1.8300 - 1.9200
52 Week Range1.5100 - 5.9400
Volume115,299
Avg. Volume125,488
Market Cap29.623M
Beta (3Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-01-20
1y Target EstN/A
  • If You Had Bought Altimmune (NASDAQ:ALT) Stock A Year Ago, You'd Be Sitting On A 48% Loss, Today
    Simply Wall St.

    If You Had Bought Altimmune (NASDAQ:ALT) Stock A Year Ago, You'd Be Sitting On A 48% Loss, Today

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

  • Barrons.com

    Why the Facebook political-ads debate could be a windfall for legacy media

    Analyst: ‘FB has made clear they do not see themselves as having the authority to make such a decision, while Twitter has taken the other side’

  • Benzinga

    Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

    Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...

  • Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
    InvestorPlace

    Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

    Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.